Table 1.
Primary performance measures for the Improving Care for Cardiovascular Disease in China-atrial fibrillation project
| Reference | Title of performance measure | Proportion, % (numerator/denominator) |
| 7, 22 | Proportion of patients with non-valvular AF in whom assessment of thromboembolic risk | 23.6 (5384/22 864) |
| 7, 22 | Proportion of AF patients with indication prescribed an anticoagulant drug at discharge* | 42.3 (6413/15 150) |
| 7, 22 | Proportion of patients discharged on warfarin who have PT/INR follow-up planned at discharge | 87.2 (7721/8857) |
| 7, 22 | Proportion of AF patients with indications receiving ACEI/ARB at discharge† | 53.1 (1794/3382) |
| 7, 22 | Proportion of AF patients with indication prescribed a beta-blocker at discharge‡ | 57.0 (1245/2184) |
| 7 | Proportion of AF patients with indication prescribed a statin at discharge§ | 61.2 (8524/13 925) |
| – | Composite scores of primary performance measures | 46.8 (31 081/66 362) |
*Indications refer to non-valvular AF patients with CHA2DS2-VASc≥2.
†Indications refer to AF patients with acute myocardial infarction; or coronary heart disease with comorbidity of hypertension, diabetes mellitus or chronic kidney disease; or left ventricular ejection fraction <40% according to the case records.
‡Indications refer to AF patients with heart failure.
§Indications refer to AF patients with coronary heart disease, ischaemic stroke/transient ischaemic attack, peripheral vascular disease or diabetes mellitus.
ACEI, ACE inhibitor; ARB, angiotensin receptor blocker.; INR, international normalised ratio; PT, prothrombin time.